Vertex Pharmaceuticals (VRTX) Financials: Revenue & Earnings
VRTX$526.11+5.08 +0.97%
$133.35B
Market Cap
29.88
P/E
28.12
Forward P/E
55
Score
Vertex Pharmaceuticals (VRTX) Financials: Revenue & Earnings
VRTX price $526.11 +5.08 +0.97%
- Ticker
- VRTX
- Price
- $526.11
- Change
- +5.08 +0.97%
- Market cap ?
- $133.35B
- P/E ?
- 29.88
- Forward P/E ?
- 28.12
- Dividend yield ?
- 0.00%
- Beta ?
- 0.32
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 55
- Value
- 21
- Quality
- 91
- Growth
- 52
Stocklytics score rationale: value 21, quality 91, growth 52.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 1702177000 | 2488652000 | 3047597000 | 4162821000 | 6205683000 | 7574400000 | 8930700000 | 9869200000 | 11020100000 | 12074600000 |
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene…
Fair value
VRTX fair value $594.85. Price $526.11. Price is 12% below fair value.
Below fair value, but more expensive than usual. A smaller discount than on 91% of days in the past 5 years.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Calculated with a 10-year free-cash-flow discount. Starting free cash flow 3.80B. Growth 20.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 8.70% (beta 0.8). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 253.46M. Net debt -1.21B. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-02 | — | 4.80 | — | 3.42B |
| 2026-08-03 | 4.73 | 4.74 | 3.33B | 3.23B |
| 2026-05-04 | 4.47 | 4.24 | 2.99B | 2.99B |
| 2026-02-12 | 5.03 | 5.11 | 3.19B | 3.18B |
| 2025-11-03 | 4.80 | 4.57 | 3.08B | 3.06B |
| 2025-08-04 | 4.52 | 4.29 | 2.96B | 2.91B |
| 2025-05-05 | 4.06 | 4.25 | 2.77B | 2.86B |
| 2025-02-10 | 3.98 | 4.02 | 2.91B | 2.78B |
| 2024-11-04 | 4.38 | 4.14 | 2.77B | 2.69B |
| 2024-08-01 | -12.83 | -11.63 | 2.63B | 2.66B |
| 2024-05-06 | 4.76 | 4.06 | 2.69B | 2.58B |
| 2024-02-05 | 4.20 | 4.10 | 2.52B | 2.51B |
| 2023-11-06 | 4.08 | 3.97 | 2.48B | 2.50B |
| 2023-08-01 | 3.89 | 3.88 | 2.49B | 2.42B |
| 2023-05-01 | 3.05 | 3.00 | 2.37B | 2.34B |
| 2023-02-07 | 3.76 | 3.51 | 2.30B | 2.30B |
| 2022-10-27 | 4.01 | 3.64 | 2.33B | 2.23B |
| 2022-08-04 | 3.60 | 3.48 | 2.20B | 2.13B |
| 2022-05-05 | 3.52 | 3.49 | 2.10B | 2.07B |
| 2022-01-26 | 3.37 | 3.30 | 2.07B | 2.00B |
| 2021-11-02 | 3.56 | 3.08 | 1.98B | 1.85B |
| 2021-07-29 | 3.11 | 2.69 | 1.79B | 1.72B |
| 2021-04-29 | 2.98 | 2.69 | 1.72B | 1.66B |
| 2021-02-01 | 2.51 | 2.59 | 1.63B | 1.58B |
| 2020-10-29 | 2.64 | 2.34 | 1.54B | 4.06B |
| 2020-07-30 | 2.61 | 2.07 | 1.52B | 1.21B |
| 2020-04-29 | 2.56 | 1.85 | 1.52B | 1.09B |
| 2020-01-30 | 1.70 | 1.21 | 1.41B | 1.01B |
| 2019-10-30 | 1.23 | 1.14 | 949.83M | 888.05M |
| 2019-07-31 | 1.26 | 1.07 | 941.29M | 799.35M |
| 2019-04-30 | 1.14 | 0.97 | 858.43M | 730.42M |
| 2019-02-05 | 1.30 | 1.05 | 870.11M | 709.47M |
| 2018-10-24 | 1.09 | 1.00 | 784.53M | 734.12M |
| 2018-07-25 | 0.94 | 0.75 | 752.16M | 600.16M |
| 2018-04-26 | 0.76 | 0.63 | 640.80M | 531.19M |
| 2018-01-31 | 0.61 | 0.58 | 651.63M | 566.14M |
| 2017-10-25 | 0.53 | 0.37 | 578.16M | 415.44M |
| 2017-07-26 | 0.39 | 0.35 | 544.13M | 488.29M |
| 2017-04-27 | 0.41 | 0.29 | 714.72M | 679.84M |
| 2017-01-25 | 0.35 | 0.26 | 458.71M | 380.07M |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-20 | Brennan Daniel J. | Buy | 795 | $503.47 | 400.26K |
| 2026-10-20 | Brennan Daniel J. | Other | 0 | — | — |
| 2026-10-15 | SACHS BRUCE I | Buy | 93 | $512.44 | 47.50K |
| 2026-10-15 | Garber Alan M | Buy | 29 | $512.44 | 15.00K |
| 2026-09-08 | van Grunsven Jasper | Buy | 8.68K | — | — |
| 2026-09-08 | van Grunsven Jasper | Other | 0 | — | — |
| 2026-08-28 | Ambrose Kristen | Buy | 5.00K | — | — |
| 2026-08-27 | SACHS BRUCE I | Sell | 6.00K | — | — |
| 2026-07-21 | Tatsis Ourania | Buy | 8.25K | — | — |
| 2026-07-21 | Sachdev Amit | Buy | 8.25K | — | — |
| 2026-07-15 | SACHS BRUCE I | Buy | 100 | $475.28 | 47.50K |
| 2026-07-15 | Garber Alan M | Buy | 32 | — | — |
| 2026-07-02 | Tatsis Ourania | Sell | 1.50K | $524.99 | 787.49K |
| 2026-07-02 | McKechnie Duncan | Sell | 1.54K | $519.00 | 799.78K |
| 2026-07-01 | Liu Joy | Sell | 828 | $502.71 | 416.24K |
| 2026-06-26 | Bozic Carmen | Sell | 596 | $482.50 | 287.57K |
| 2026-06-18 | Bozic Carmen | Sell | 1.02K | $462.17 | 471.41K |
| 2026-06-15 | Bozic Carmen | Sell | 4.06K | $450.00 | 1.83M |
| 2026-06-05 | Bozic Carmen | Sell | 1.75K | $450.00 | 785.25K |
| 2026-05-29 | Bozic Carmen | Sell | 1.97K | $450.00 | 888.30K |
| 2026-05-15 | Bunnage Mark E. | Sell | 33 | $453.45 | 14.96K |
| 2026-05-15 | Bozic Carmen | Sell | 1.35K | $453.45 | 613.97K |
| 2026-05-12 | Bozic Carmen | Sell | 6.99K | $450.00 | 3.14M |
| 2026-05-04 | Bhatia Sangeeta N. | Sell | 318 | $423.73 | 134.75K |
| 2026-05-01 | Upadhyay Suketu | Buy | 796 | — | — |
| 2026-05-01 | Upadhyay Suketu | Buy | 2.87K | $424.45 | 1.22M |
| 2026-05-01 | Upadhyay Suketu | Sell | 796 | — | — |
| 2026-05-01 | Thornberry Nancy | Buy | 472 | — | — |
| 2026-05-01 | Thornberry Nancy | Sell | 398 | — | — |
| 2026-05-01 | Thornberry Nancy | Buy | 1.43K | $424.45 | 608.24K |
| 2026-05-01 | Thornberry Nancy | Buy | 398 | — | — |
| 2026-05-01 | Schneider Jennifer | Buy | 472 | — | — |
| 2026-05-01 | Schneider Jennifer | Buy | 1.43K | $424.45 | 608.24K |
| 2026-05-01 | Schneider Jennifer | Sell | 796 | — | — |
| 2026-05-01 | Schneider Jennifer | Buy | 796 | — | — |
| 2026-05-01 | SACHS BRUCE I | Buy | 2.87K | $424.45 | 1.22M |
| 2026-05-01 | MCKENZIE DIANA | Buy | 796 | — | — |
| 2026-05-01 | MCKENZIE DIANA | Buy | 943 | — | — |
| 2026-05-01 | MCKENZIE DIANA | Sell | 796 | — | — |
| 2026-05-01 | Liu Joy | Sell | 1.10K | $425.02 | 469.22K |
| 2026-05-01 | Lagarde Michel | Buy | 2.87K | $424.45 | 1.22M |
| 2026-05-01 | Garber Alan M | Buy | 472 | — | — |
| 2026-05-01 | Garber Alan M | Buy | 1.43K | $424.45 | 608.24K |
| 2026-05-01 | CARNEY LLOYD | Buy | 2.87K | $424.45 | 1.22M |
| 2026-05-01 | Bhatia Sangeeta N. | Buy | 943 | — | — |
| 2026-04-15 | Upadhyay Suketu | Buy | 81 | — | — |
| 2026-04-15 | SACHS BRUCE I | Buy | 107 | — | — |
| 2026-04-15 | Garber Alan M | Buy | 34 | — | — |
| 2026-04-01 | Liu Joy | Sell | 978 | $449.17 | 439.29K |
| 2026-03-27 | Bozic Carmen | Sell | 2.33K | $450.95 | 1.05M |
| 2026-03-13 | Bozic Carmen | Sell | 2.33K | $481.79 | 1.12M |
| 2026-03-11 | McKechnie Duncan | Sell | 2.63K | $498.42 | 1.31M |
| 2026-03-04 | McKechnie Duncan | Sell | 2.44K | $475.30 | 1.16M |
| 2026-03-02 | Liu Joy | Sell | 892 | $495.96 | 442.40K |
| 2026-03-01 | Liu Joy | Other | 0 | — | — |
| 2026-03-01 | Liu Joy | Other | 7.04K | $155.57 | 1.10M |
| 2026-03-01 | Liu Joy | Other | 5.36K | $187.53 | 1.01M |
| 2026-02-27 | Kewalramani Reshma | Sell | 400 | $479.75 | 191.90K |
| 2026-02-27 | Kewalramani Reshma | Sell | 120 | $481.50 | 57.78K |
| 2026-02-27 | Kewalramani Reshma | Sell | 240 | $482.84 | 115.88K |
| 2026-02-27 | Kewalramani Reshma | Sell | 2.51K | $487.13 | 1.22M |
| 2026-02-27 | Kewalramani Reshma | Sell | 3.28K | $488.27 | 1.60M |
| 2026-02-27 | Kewalramani Reshma | Sell | 460 | $489.32 | 225.09K |
| 2026-02-27 | Kewalramani Reshma | Sell | 2.73K | $490.54 | 1.34M |
| 2026-02-27 | Kewalramani Reshma | Sell | 949 | $491.30 | 466.24K |
| 2026-02-27 | Kewalramani Reshma | Sell | 2.52K | $493.29 | 1.24M |
| 2026-02-27 | Kewalramani Reshma | Sell | 3.50K | $494.33 | 1.73M |
| 2026-02-27 | Kewalramani Reshma | Sell | 15.58K | $495.38 | 7.72M |
| 2026-02-27 | Kewalramani Reshma | Sell | 6.00K | $496.16 | 2.97M |
| 2026-02-27 | Kewalramani Reshma | Sell | 1.73K | $496.95 | 857.24K |
| 2026-02-27 | Bozic Carmen | Sell | 2.33K | $480.31 | 1.12M |
| 2026-02-26 | Ambrose Kristen | Sell | 357 | $483.36 | 172.56K |
| 2026-02-25 | Tatsis Ourania | Sell | 260 | $486.35 | 126.45K |
| 2026-02-25 | Sachdev Amit | Sell | 1.85K | $486.35 | 897.80K |
| 2026-02-25 | McKechnie Duncan | Sell | 2.50K | $486.35 | 1.22M |
| 2026-02-25 | McKechnie Duncan | Sell | 2.41K | $489.00 | 1.18M |
| 2026-02-25 | Bunnage Mark E. | Sell | 620 | $486.35 | 301.54K |
| 2026-02-25 | Biller Jonathan | Sell | 945 | $486.35 | 459.60K |
| 2026-02-25 | Atkinson Edward Morrow III | Sell | 668 | $486.35 | 324.88K |
| 2026-02-25 | Ambrose Kristen | Sell | 223 | $486.35 | 108.46K |
| 2026-02-24 | WAGNER CHARLES F JR | Sell | 1.74K | $485.11 | 846.03K |
| 2026-02-24 | Tatsis Ourania | Sell | 1.63K | $485.11 | 789.27K |
| 2026-02-24 | Sachdev Amit | Sell | 1.52K | $485.11 | 736.40K |
| 2026-02-24 | McKechnie Duncan | Sell | 873 | $485.11 | 423.50K |
| 2026-02-24 | LEIDEN JEFFREY M | Sell | 3.55K | $485.11 | 1.72M |
| 2026-02-24 | Kewalramani Reshma | Sell | 4.98K | $485.11 | 2.42M |
| 2026-02-24 | Bunnage Mark E. | Sell | 582 | $485.11 | 282.33K |
| 2026-02-24 | Bozic Carmen | Sell | 1.45K | $485.11 | 704.86K |
| 2026-02-24 | Biller Jonathan | Sell | 1.14K | $485.11 | 554.97K |
| 2026-02-24 | Atkinson Edward Morrow III | Sell | 1.63K | $485.11 | 789.27K |
| 2026-02-24 | Ambrose Kristen | Sell | 546 | $485.11 | 264.87K |
| 2026-02-19 | Sachdev Amit | Buy | 25.03K | $187.53 | 4.69M |
| 2026-02-19 | Sachdev Amit | Sell | 920 | $463.91 | 426.80K |
| 2026-02-19 | Sachdev Amit | Sell | 2.73K | $465.05 | 1.27M |
| 2026-02-19 | Sachdev Amit | Sell | 1.85K | $465.80 | 860.80K |
| 2026-02-19 | Sachdev Amit | Sell | 10.26K | $467.75 | 4.80M |
| 2026-02-19 | Sachdev Amit | Buy | 23.48K | $155.57 | 3.65M |
| 2026-02-19 | Sachdev Amit | Sell | 19.66K | $468.57 | 9.21M |
| 2026-02-19 | Sachdev Amit | Sell | 7.24K | $469.61 | 3.40M |
| 2026-02-19 | Sachdev Amit | Sell | 11.71K | $470.54 | 5.51M |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 1.82K, holders +59 vs prior quarter. Ownership 95.84%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| CAPITAL WORLD INVESTORS | 26.12M | 746.89K | +2.94% | 12.97B |
| BLACKROCK, INC. | 24.11M | 139.86K | +0.58% | 11.98B |
| CAPITAL RESEARCH GLOBAL INVESTORS | 19.49M | -1.64M | -7.74% | 9.68B |
| VANGUARD CAPITAL MANAGEMENT LLC | 16.58M | 67.90K | +0.41% | 8.24B |
| STATE STREET CORP | 11.87M | 141.32K | +1.20% | 5.90B |
| INVESCO LTD. | 8.04M | 2.71M | +50.86% | 4.00B |
| JPMORGAN CHASE & CO | 6.52M | -515.56K | -7.33% | 3.26B |
| GEODE CAPITAL MANAGEMENT, LLC | 6.02M | -121.77K | -1.98% | 2.98B |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.88M | -266.62K | -5.18% | 2.42B |
| CAPITAL INTERNATIONAL INVESTORS | 4.70M | -430.93K | -8.41% | 2.33B |
| LOOMIS SAYLES & CO L P | 3.92M | -82.87K | -2.07% | 1.95B |
| FRANKLIN TEMPLETON INC | 3.35M | 2.80M | +507.34% | 1.66B |
| WELLINGTON MANAGEMENT GROUP LLP | 3.25M | 35.07K | +1.09% | 1.61B |
| MORGAN STANLEY | 3.24M | 53.26K | +1.67% | 1.61B |
| UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC | 3.09M | 29.29K | +0.96% | 1.53B |
| BANK OF AMERICA CORP /DE/ | 3.04M | 161.00K | +5.59% | 1.51B |
| JENNISON ASSOCIATES LLC | 3.00M | 258.47K | +9.43% | 1.49B |
| NORGES BANK | 2.97M | 2.97M | New | 1.48B |
| ALLIANCEBERNSTEIN L.P. | 3.02M | -891.47K | -22.80% | 1.35B |
| AMERIPRISE FINANCIAL INC | 2.60M | -28.66K | -1.09% | 1.29B |
| NORTHERN TRUST CORP | 2.49M | -77.79K | -3.03% | 1.24B |
| GOLDMAN SACHS GROUP INC | 2.48M | 63.89K | +2.64% | 1.23B |
| CLEARBRIDGE INVESTMENTS, LLC | 2.34M | -358.06K | -13.26% | 1.16B |
| VICTORY CAPITAL MANAGEMENT INC | 2.17M | 284.63K | +15.07% | 1.08B |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2.04M | 120.41K | +6.27% | 1.01B |
Earnings and financials
Vertex Pharmaceuticals Incorporated (VRTX) trades at $526.11, with a market cap of $133.35B and a trailing P/E of 29.88. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 1702177000 | 2488652000 | 3047597000 | 4162821000 | 6205683000 | 7574400000 | 8930700000 | 9869200000 | 11020100000 | 12074600000 |
Insights · Dividends · Forecast · Financials · Learn